REMI — Remedent Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro Cap

Annual income statement for Remedent, fiscal year end - March 31st, USD millions except per share, conversion factor applied.

	2016 March 31st	2017 March 31st	2018 March 31st	2019 March 31st	2020 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2.77	2.36	2.7	1.6	1.06
Cost of Revenue
Gross Profit	1.95	1.19	1.78	1.12	0.742
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	2.76	2.18	3	2.32	1.54
Operating Profit	0.007	0.178	-0.301	-0.717	-0.48
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	0.2	0.823	-0.042	2.12	-0.852
Provision for Income Taxes
Net Income After Taxes	0.177	0.827	-0.043	2.12	-0.854
Minority Interest
Net Income Before Extraordinary Items
Net Income	0.161	0.844	-0.055	2.13	-0.858
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	0.161	0.844	-0.055	2.13	-0.858
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.008	0.002	-0.003	0.106	-0.043